DE69721810D1 - Konjugate zur behandlung von prostatakrebs - Google Patents

Konjugate zur behandlung von prostatakrebs

Info

Publication number
DE69721810D1
DE69721810D1 DE69721810T DE69721810T DE69721810D1 DE 69721810 D1 DE69721810 D1 DE 69721810D1 DE 69721810 T DE69721810 T DE 69721810T DE 69721810 T DE69721810 T DE 69721810T DE 69721810 D1 DE69721810 D1 DE 69721810D1
Authority
DE
Germany
Prior art keywords
conjugates
prostate cancer
treating prostate
treating
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69721810T
Other languages
English (en)
Other versions
DE69721810T2 (de
Inventor
M Garsky
Dong-Mei Feng
Deborah Defeo-Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9626309.0A external-priority patent/GB9626309D0/en
Priority claimed from GBGB9718160.6A external-priority patent/GB9718160D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of DE69721810D1 publication Critical patent/DE69721810D1/de
Publication of DE69721810T2 publication Critical patent/DE69721810T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69721810T 1996-10-30 1997-10-27 Konjugate zur behandlung von prostatakrebs Expired - Fee Related DE69721810T2 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US2922496P 1996-10-30 1996-10-30
US29224P 1996-10-30
GBGB9626309.0A GB9626309D0 (en) 1996-12-18 1996-12-18 Conjugates useful in the treatment of prostate cancer
GB9626309 1996-12-18
US4292197P 1997-04-04 1997-04-04
US42921P 1997-04-04
GBGB9718160.6A GB9718160D0 (en) 1997-08-28 1997-08-28 Conjugates useful in the treatment of prostate cancer
GB9718160 1997-08-28
PCT/US1997/019225 WO1998018493A2 (en) 1996-10-30 1997-10-27 Conjugates useful in the treatment of prostate cancer

Publications (2)

Publication Number Publication Date
DE69721810D1 true DE69721810D1 (de) 2003-06-12
DE69721810T2 DE69721810T2 (de) 2004-03-11

Family

ID=27451580

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69721810T Expired - Fee Related DE69721810T2 (de) 1996-10-30 1997-10-27 Konjugate zur behandlung von prostatakrebs

Country Status (32)

Country Link
EP (1) EP0942754B1 (de)
JP (1) JP2000509407A (de)
KR (1) KR100508199B1 (de)
AR (1) AR008907A1 (de)
AT (1) ATE239509T1 (de)
AU (1) AU726434B2 (de)
BG (1) BG64768B1 (de)
BR (1) BR9712589A (de)
CA (1) CA2268738A1 (de)
CO (1) CO4930281A1 (de)
CZ (1) CZ155599A3 (de)
DE (1) DE69721810T2 (de)
DK (1) DK0942754T3 (de)
DZ (1) DZ2333A1 (de)
EA (1) EA002066B1 (de)
EE (1) EE03858B1 (de)
ES (1) ES2196374T3 (de)
HK (1) HK1024876A1 (de)
HR (1) HRP970566A2 (de)
HU (1) HUP0000651A3 (de)
ID (1) ID21358A (de)
IL (1) IL129356A0 (de)
IS (1) IS5025A (de)
NO (1) NO992069L (de)
PE (1) PE17399A1 (de)
PL (1) PL333004A1 (de)
PT (1) PT942754E (de)
SK (1) SK57399A3 (de)
TR (1) TR199901485T2 (de)
TW (1) TW425286B (de)
WO (1) WO1998018493A2 (de)
YU (1) YU21399A (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA002745B1 (ru) * 1997-12-02 2002-08-29 Мерк Энд Ко., Инк. Конъюгаты, которые можно использовать при лечении рака предстательной железы
CA2238257A1 (en) * 1998-05-22 1999-11-22 Universite De Montreal Endocytosis of amf-r and uses thereof in cancer therapy
AU764603B2 (en) * 1998-07-17 2003-08-21 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Water-soluble drugs and methods for their production
US6174858B1 (en) 1998-11-17 2001-01-16 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
DK1144011T3 (da) * 1998-12-11 2010-07-05 Coulter Pharm Inc Pro-drug-forbindelser og fremgangsmåde til fremstilling deraf
WO2001028593A2 (en) * 1999-10-19 2001-04-26 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
GB9924759D0 (en) 1999-10-19 1999-12-22 Merck Sharp & Dohme Process for preparing peptide intermediates
CA2387901A1 (en) * 1999-10-27 2001-05-03 Merck & Co., Inc. Salt form of a conjugate useful in the treatment of prostate cancer
MXPA02009019A (es) * 2000-03-15 2003-02-12 Du Pont Pharm Co Farmacos antineoplasticos de objetivo, que se desdoblan por la peptidasa y su uso terapeutico.
EP1490090A4 (de) * 2002-02-22 2006-09-20 New River Pharmaceuticals Inc Wirkstoff-abgabesystem und verfahren zum schutz und zur verabreichung von wirkstoffen
US20050187147A1 (en) * 2003-09-22 2005-08-25 Newman Michael J. Compositions and methods for increasing drug efficiency
CN100372862C (zh) * 2003-11-05 2008-03-05 天津和美生物技术有限公司 具有抗癌活性的阿霉素衍生物及其制备方法和应用
WO2008067495A2 (en) * 2006-11-29 2008-06-05 Rutgers, The State University Of New Jersey Chemotherapeutic conjugates and methods of use
CN101225094A (zh) * 2007-01-18 2008-07-23 天津和美生物技术有限公司 具有抗癌活性的蒽醌四环类化合物
KR101472316B1 (ko) * 2009-03-09 2014-12-12 케이티비 투머포슝스케쉘샤프트 엠비에이치 프로드러그
WO2012123755A1 (en) 2011-03-17 2012-09-20 The University Of Birmingham Re-directed immunotherapy
MX358660B (es) 2012-01-12 2018-08-30 Univ Yale Compuestos y metodos para degradacion mejorada de proteinas y otros polipeptidos elegidos como blanco mediante una ubiquitina ligasa e3.
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
CA2971288A1 (en) 2015-02-02 2016-08-11 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes
ES2873846T3 (es) 2015-11-19 2021-11-04 Revitope Ltd Complementación de fragmento de anticuerpo funcional para un sistema de dos componentes para eliminación redirigida de células no deseadas
CA3203072A1 (en) 2020-12-22 2022-06-30 Andrea CASAZZA Compounds comprising a tetrapeptidic moiety
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US6143864A (en) * 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
AU708475B2 (en) * 1995-10-18 1999-08-05 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia

Also Published As

Publication number Publication date
WO1998018493A3 (en) 1998-07-23
CZ155599A3 (cs) 1999-10-13
AU726434B2 (en) 2000-11-09
HUP0000651A2 (hu) 2000-06-28
PE17399A1 (es) 1999-02-20
HRP970566A2 (en) 1998-08-31
AR008907A1 (es) 2000-02-23
NO992069D0 (no) 1999-04-29
BG64768B1 (bg) 2006-03-31
SK57399A3 (en) 2000-01-18
CO4930281A1 (es) 2000-06-27
EA002066B1 (ru) 2001-12-24
DE69721810T2 (de) 2004-03-11
KR100508199B1 (ko) 2005-08-17
BG103436A (en) 2000-04-28
BR9712589A (pt) 1999-10-26
EP0942754A2 (de) 1999-09-22
ID21358A (id) 1999-05-27
HUP0000651A3 (en) 2001-12-28
WO1998018493A2 (en) 1998-05-07
EP0942754B1 (de) 2003-05-07
HK1024876A1 (en) 2000-10-27
ATE239509T1 (de) 2003-05-15
TW425286B (en) 2001-03-11
KR20000052970A (ko) 2000-08-25
JP2000509407A (ja) 2000-07-25
YU21399A (sh) 2000-03-21
PT942754E (pt) 2003-08-29
IL129356A0 (en) 2000-02-17
AU5149798A (en) 1998-05-22
IS5025A (is) 1999-04-13
NO992069L (no) 1999-06-30
DZ2333A1 (fr) 2002-12-28
ES2196374T3 (es) 2003-12-16
EE9900179A (et) 1999-12-15
EA199900428A1 (ru) 2000-02-28
TR199901485T2 (xx) 1999-08-23
DK0942754T3 (da) 2003-08-04
PL333004A1 (en) 1999-11-08
CA2268738A1 (en) 1998-05-07
EE03858B1 (et) 2002-10-15

Similar Documents

Publication Publication Date Title
DE69721810D1 (de) Konjugate zur behandlung von prostatakrebs
NO984431D0 (no) FremgangsmÕte for behandling av smerte
FI970918A (fi) Yhdisteet ja menetelmät syövän hoitamiseksi
EP0926955A4 (de) Konjugate nützlich in die behandlung von prostatakarzinom
DE59709729D1 (de) Vorrichtung zum Behandeln von malignen Gewebsveränderungen
HUP0000261A3 (en) Means for treating prostate hypertrophy and prostate cancer
DE69705438D1 (de) Bodenbehandlungsmaschine
NO974972L (no) FremgangsmÕte for Õ hindre brystcancer
DE69729004D1 (de) Photodynamische therapie zur behandlung von osteosrthritis
FI965008A (fi) Koostumukset ja menetelmät kasvainten hoitamiseksi
DE29704898U1 (de) Bestrahlungseinrichtung
DZ2665A1 (fr) Conjugués utiles pour le traitement du cancer de la prostate.
NO984446D0 (no) FremgangsmÕte for behandling av smerte
DE69721756D1 (de) Paroxetine zur behandlung von depression
ATE250580T1 (de) Substituierte pyridino-arylpiperazine zur behandlung benigner prostatahyperplasie
IDP000008233A (id) Metode pencegahan kanker payudara
DE69806062D1 (de) Kombinationstherapie zur behandlung von aids
ZA9810974B (en) Conjugates useful in the treatment of prostate cancer
DE69706195D1 (de) Antikonvulsive derivate zur behandlung von psoriasis
GB9903035D0 (en) Treating cancer
ZA978162B (en) Means for treating prostate hypertrophy and prostate cancer.
GB2334579B (en) Treating cancer
ZA979655B (en) Conjugates useful in the treatment of prostate cancer.
BR9700778A (pt) Métodos de inibição de tumores do cólon
GB9812151D0 (en) Treating cancer

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee